| Identification | Back Directory | [Name]
N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide | [CAS]
633698-99-4 | [Synonyms]
LF220542
LF-220542
LF22-0542
LF 220542
LF 22-0542
Safotibant
LF-22-0542
N-(4-(4,5-Dihydro-1H-imidazol-2-yl)benzyl)-2-(2-(4-methoxy-N,2,6-trimethylphenylsulfonamido)ethoxy)-N-methylacetamide
N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide
Acetamide, N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]-N-methyl- | [Molecular Formula]
C25H34N4O5S | [MDL Number]
MFCD30747866 | [MOL File]
633698-99-4.mol | [Molecular Weight]
502.626 |
| Hazard Information | Back Directory | [Uses]
Safotibant is a reagent with pharmocological activity to inhibited retinal inflammation and oxidative stress in rat with Zanosar induced diabetes | [in vivo]
Safotibant (10 mg/kg, s.c., 3 times a day for 8 days) exhibits analgesic property against bone cancer-induced pain in osteolytic sarcoma xenograft C3H/HeJ mice model, without affecting disease progression[1].
Safotibant (one eye drop application, twice a day for 7 days) inhibits expressions of inflammatory mediators B1R, iNOS, IL-1β, COX-2, VEGF-R2 and HIF-1α, reverses diabetes-induced retinal inflammation and oxidative stress in streptozotocin (STZ)-diabetic Wistar rats model[2]. | Animal Model: | Osteolytic sarcoma xenograft C3H/HeJ mice model[1] | | Dosage: | 10 mg/kg | | Administration: | s.c., 3 times a day for 8 days | | Result: | Decreased numbers of flinching and time spent on spontaneous guarding. |
| Animal Model: | Streptozotocin (STZ)-diabetic Wistar rats model[2] | | Dosage: | One eye drop | | Administration: | On eyes application, twice a day for 7 days | | Result: | Reversed retinal vascular hyperpermeability, decreased levels of retinal leukostasis and superoxide anion in 3 retinal nuclear layers. |
|
|
|